Seeking Alpha

IPOdesktop

 
View as an RSS Feed
View IPOdesktop's Articles BY TICKER:
AAC, AAOI, AAVL, ABCW, ABDC, ABHB, ABY, ACRE, ACTV, ADHD, ADMS, ADNC, ADPT, ADSI, AERI, AFMD, AGMX, AGRX, AGTC, AHH, AKAO, AKBA, AL, ALDR, ALDW, ALDX, ALLY, ALSN, AMBA, AMBR, AMBX, AMC, AMDA, AMH, AMID, AMPH, AMRE, AMTG, ANET, ANFI, ANGI, APAM, APO, AQ, AQXP, AR, ARBR, ARCO, ARCX, ARDX, ARES, ARGS, ARMK, ARPI, ARS, ASC, ASPN, ATEN, ATHL, ATHM, ATRA, ATTO, AURX, AVG, AVIV, AVOL, AWAY, AXTA, BABA, BATS, BCC, BCEI, BCOV, BCRH, BERY, BFAM, BIND, BIOA, BLMN, BLOX, BLUE, BNFT, BNK, BNNY, BRDR, BRG, BRSE, BRSS, BRX, BSTM, BURL, BV, CAHS, CALA, CAPL, CAPN, CARA, CARB, CARH, CBF, CBIO, CCCR, CCFG, CCLP, CCS, CCXI, CDNA, CELP, CEMP, CERE, CERU, CFG, CFRX, CG, CGIX, CHEF, CHGG, CHKR, CHUY, CIO, CIVI, CJES, CK, CLDN, CLVS, CMCM, CMFN, CMLP, CNCE, CNNX, CNOB, CNV, CNXR, COMM, CONE, CORI, COTY, COUP, COVS, CQH, CRCM, CRSR, CRTO, CSLT, CSOD, CSTE, CSTM, CTLT, CTRL, CTT, CUDA, CVRR, CVT, CYBR, CYNI, CZR, DATA, DATE, DCIN, DDMGQ, DERM, DFRG, DKL, DLNG, DLPH, DM, DMD, DNKN, DOC, DOR, DPLO, DPRX, DRII, DRNA, DRTX, DSG, DSKY, DWRE, EAC, EARN, EARS, EBIO, ECOM, ECR, EDG, EGRX, EHIC, EIGI, ELLI, ELOQ, EMES, ENBL, ENPH, ENTA, ENVI, ENXP, EOPN, EPAM, EPE, EPZM, EQM, ESNT, ESRT, ET, EVDY, EVER, EVHC, EVOK, EXA, EYEG, EYES, FATE, FB, FCB, FELP, FENG, FET, FEYE, FFNT, FFWM, FGEN, FGL, FI, FIO, FIVE, FIVN, FLTX, FLXN, FMI, FMSA, FNDR, FOMX, FOXF, FPI, FPRX, FRAC, FRAN, FRSH, FSAM, FSL, FSTM, FUEL, FWP, FX, FXCM, GARS, GBIM, GCAP, GCTS, GDCT, GFIS, GIMO, GLMD, GLOB, GLOG, GLOP, GLYC, GMED, GNBC, GOGO, GOMO, GPRO, GRPN, GRUB, GSE, GWAY, GWB, GWGH, GWRE, HABT, HASI, HAWK, HCLP, HDP, HDS, HELI, HIIQ, HIVE, HLSS, HLT, HMHC, HMLP, HMST, HPTX, HQY, HRTG, HSGX, HUBS, HZNP, I, IBP, IBTX, ICC, ICD, ICPT, IMDZ, IMI, IMPR, IMPV, IMS, INGN, INNL, INSY, INVN, IPDN, IRT, JD, JGW, JIVE, JMEI, JMI, JPEP, JRVR, KANG, KBIO, KIN, KING, KIOR, KITE, KMI, KNMD, KORS, KOS, KPTI, KTWO, KYAK, KYTH, LADR, LAEC, LAND, LC, LDRH, LEAF, LEJU, LGIH, LITB, LLGX, LMNS, LMRK, LNKD, LNTH, LOCK, LOCO, LOXO, LPDX, LPI, LPRI, LQ, LRE, LUCA, LXFR, MACK, MAPI, MBII, MBLY, MBUU, MC, MCEP, MCLB, MCUR, MDLY, MDWD, MEMP, MEP, MFRM, MGNX, MIK, MITT, MKTG, MKTO, MM, MMI, MN, MOBL, MODL, MODN, MOLG, MOMO, MONT, MPG, MPLX, MPO, MRC, MRCC, MRD, MRIN, MRKT, MRNS, MSBI, MTBC, MTDR, MTGE, MTLS, MTSI, MVNR, MYCC, NAP, NBCB, NBHC, NCFT, NCLH, NDLS, NDRM, NDRO, NEFF, NEOT, NEP, NERV, NEWR, NGL, NGVC, NLNK, NMBL, NMFC, NMIH, NORD, NOW, NQ, NRE, NRKM, NRX, NSE, NSIG, NSLP, NSM, NTI, NVGS, NWHM, NYLD, OAK, OAKS, OCIR, OCUL, OEC, OFS, OILT, OMAM, OMED, ONDK, OPB, OPHT, OPWR, ORC, ORPN, OTIC, OUT, OXFD, P, PAGP, PAHC, PANW, PARN, PAYC, PBF, PBFX, PCTY, PDH, PE, PEAK, PEER, PEGI, PER, PETX, PF, PFMT, PFNX, PFPT, PFSI, PGEM, PGRE, PIH, PINC, PLAY, PMCA, PRAH, PRLB, PRQR, PRSS, PRTO, PSMI, PSRT, PSXP, PTLA, Q, QEPM, QGOG, QIHU, QIWI, QLYS, QRE, QTNT, QTS, QTWO, QUNR, RARE, RATE, RBIO, RCAP, RCPT, RDUS, REGI, RENN, REPH, REXR, RGDO, RGLS, RH, RIBX, RICE, RIGP, RKUS, RLGY, RLJ, RLYP, RM, RMAX, RMP, RNA, RNDY, RNF, RNG, ROYT, RPAI, RPXC, RRMS, RSPP, RTGN, RUBI, RVNC, RWLK, RXN, RYI, SABR, SAGE, SALE, SAMG, SAVE, SBUX, SBY, SC, SCAI, SCM, SCRT, SCTY, SCYX, SDLP, SDR, SEAS, SEMI, SERV, SFBS, SFM, SFS, SFXE, SGLX, SGM, SGNL, SGNT, SIR, SIRI, SKIS, SKUL, SLCA, SMLP, SMLR, SMSMY, SMTH, SN, SNDX, SNOW, SNS, SPKE, SPLK, SPPP, SPWH, SQBK, SQNS, SRC, SRLP, SRVA, SSNI, SSTK, STAY, STCK, STIM, STIR, STML, STOR, STST, SUN, SUNS, SUPN, SXC, SXCP, SXE, SYF, SYNC, SZYM, TAG, TAM, TAOM, TBRA, TCPI, TCS, TEDU, TEP, TERP, THNX, THR, TKAI, TLMR, TLOG, TLYS, TMG, TMS, TMWE, TNDM, TNET, TNGO, TOUR, TOYS, TPH, TPRE, TPVG, TRIV, TRLA, TRMR, TRUE, TRUP, TRVN, TSC, TSE, TSLX, TSQ, TSRO, TTOO, TTPH, TUBE, TUDO, TUMI, TVPT, TWAV, TWOU, TWTR, TXTR, UAGR, UAN, UBNT, UCP, USAC, USDP, VA, VBAY, VBLT, VBTX, VCRA, VCYT, VEBM, VEEV, VEI, VHS, VIPS, VJET, VKTX, VLP, VLRS, VMEM, VNCE, VNET, VNOM, VNTV, VOC, VOYA, VRNS, VSAR, VSLR, VSTM, VTAE, VTL, VTTI, VWR, W, WAGE, WAIR, WB, WBAI, WGH, WGP, WHF, WHSM, WHZ, WIFI, WIX, WK, WLKP, WMC, WMS, WNRL, WPT, WSTC, WUBA, WWAV, XENE, XENT, XLRN, XNCR, XNET, XON, XONE, XOOM, YDLE, YELP, YNDX, YUME, YY, Z, ZAYO, ZEN, ZFC, ZFGN, ZLTQ, ZNGA, ZOES, ZPIN, ZSAN, ZSPH, ZTS, ZU, ZX
  • IPO Preview: OnDeck Capital
    Today, 12:10 AM ONDK Comment!

    Summary

    • Online platform for small business lending. ONDK is seeking to transform small business lending by making it efficient and convenient for small businesses to access capital.
    • Different business model than LendingClub.
    • LC is a platform that collects transaction fees but doesn't retain term loans. LC is not subject to credit risks. ONDK retains term loans, like a bank or finance company.
    • Gross revenue +156%. Loan losses 44% of gross revenue. Funding costs 12% of gross revenue.
    • Net revenue +193%. Operating loss -10% of net revenue. Adjusted loss -8% of net revenue. P/E of -222 means cash burn rate vs. market cap is relatively low.
  • IPO Preview: Rice Midstream Partners LP
    Today, 12:04 AM RMP Comment!

    Summary

    • A fee-based, growth-oriented limited partnership formed by Rice Energy Inc. to own, operate, develop and acquire midstream assets in the Appalachian Basin.
    • Expected to yield 3.75% at the price range mid-point of $20.
    • Selling 43% on the IPO, higher than recent new MLP/LPs.
    • Recent midstream IPOs off -16% in last 30 days. Parent RICE also off -16% in last 30 days. 3rd-party revenues projected to be 24%.
  • IPO Preview: New Relic
    Fri, Dec. 12 NEWR Comment!

    Summary

    • Building a new category of enterprise software it calls Software Analytics.
    • Revenue +83%; gross profit of 81%; Loss rate of -40%.
    • 250,000 users, 10,590 paid accounts.
    • Price-to-sales of 8.7; P/E of -22.5; Price-to-book of 4.4.
  • IPO Preview: Hortonworks
    Fri, Dec. 12 HDP Comment!

    Summary

    • Mission is to establish Hadoop as the foundational technology of the modern enterprise data architecture.
    • Revenues +109%; 34% gross profit. Loss rate is -260%.
    • Price-to-book of 3.4. Price-to-sales of 12.1.
  • IPO Preview: Workiva
    Fri, Dec. 12 WK Comment!

    Summary

    • Cloud-based and mobile-enabled platform for enterprises to collaboratively collect, manage, report and analyze critical business data in real time.
    • Revenue +34%; 71% gross profit. Into 60% of Fortune 100 and 500 companies.
    • Loss rate of -34%; never made money. P/E of -14.6. Price-to-sales of 5. Price to book of 7.6.
  • IPO Preview: Connecture
    Fri, Dec. 12 CNXR Comment!

    Summary

    • A leading web-based consumer shopping, enrollment and retention platform for health insurance distribution.
    • Rev +70%, loss rate is -26%. Never been profitable.
    • Per share dilution of -$15.72 is higher than IPO mid-range of $13. Accumulated deficit of -$130mm.
    • P/E of -13.5. Price-to-tangible book is -4.8. Price-to-book is -20.
  • IPO Preview: Metaldyne Performance Group
    Fri, Dec. 12 MPG Comment!

    Summary

    • A leading provider of highly-engineered components for use in Powertrain and Safety-Critical Platforms for the global light, commercial and industrial vehicle markets.
    • 100% to selling shareholder.
    • Revenue +4%; 16% gross profit; 10.5 P/E; .4 price-to-sales; -1.1 price-to-tangible book.
    • Net income +73% (preparing for IPO), growth can't be sustained. .46% dividend rate, too low to be meaningful.
  • IPO Preview: James River Group Holdings
    Fri, Dec. 12 JRVR 1 Comment

    Summary

    • Bermuda-based insurance holding company that owns and operates a group of specialty insurance and reinsurance companies.
    • 100% by selling shareholders; Goldman is selling most of its shares.
    • Rev +8%. P/E of 13.7.
    • Price-to-book of .8. Price-to-tangible book of 1.1.
  • IPO Preview: Avolon Holdings Limited
    Fri, Dec. 12 AVOL Comment!

    Summary

    • A leading global aircraft leasing company focused on acquiring, managing and selling commercial aircraft.
    • Priced in same range as AerCap. Discount to Air Lease.
    • Rev +33%; net income +12%.
    • 12.9 P/E; price-to-sales of 3.1. Price-to-book of 1.3. 3% tax rate.
  • IPO Preview: Lending Club
    Thu, Dec. 11 LC 2 Comments

    Summary

    • World’s largest online marketplace connecting borrowers and investors.
    • Rev +122%. Operating income +176%.
    • Price-to-sales of 21, definitely in the high range. Price-to-book of 6.1.
  • IPO Preview: Momo
    Thu, Dec. 11 MOMO Comment!

    Summary

    • Mobile-based social networking platform. MOMO enables users to establish and expand social relationships based on location and interests.
    • Rev +60%. Loss -87% of rev.
    • Price-to-sales of 73 (too high).
    • Per share dilution -$-11.30 vs IPO mid-range of $13.5.
  • IPO Preview: Polar Star Realty Trust
    Thu, Dec. 11 PSRT 1 Comment

    Summary

    • REIT that acquires, owns, leases, manages and redevelops office and industrial properties located primarily in Norway, Sweden and Denmark.
    • Expected yield of 6%.
    • Price-to-book of 1.8. Price-to-tangible book of 1.2. Apparent accounting inconsistency because priced to tangible book should always be equal to or greater than price-to-book.
  • IPO Preview: Histogenics
    Wed, Dec. 3 HSGX 2 Comments

    Summary

    • Egenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace.
    • The first product candidate, NeoCart, is being investigated in a Phase 3 clinical trial: regenerates cartilage.
    • Caveat: High cash burn rate relative to market cap: P/E of -5.1. Price to book: 2.8.
  • IPO Preview: Neff Corporation
    Fri, Nov. 21 NEFF 2 Comments

    Summary

    • A leading regional equipment rental company in the United States, focused on the fast-growing Sunbelt states.
    • Per share dilution is 226% of mid-range price.
    • Proforma Interest expense is 72% of operating income. NEFF proforma Sept 9 mos P/E of 84, too high.
    • NEFF P/E of 44 based on proforma 2013. URI & HEES have P/Es of around 25.
    • Only NEFF has a negative book value, compared to URI & HEES.
  • IPO Preview: Peak Resorts
    Fri, Nov. 21 SKIS 1 Comment

    Summary

    • Currently operates 13 ski resorts primarily located in the Northeast and Midwest, 12 of which SKIS owns.
    • Selling 71% on IPO, a weaknesss.
    • Results depend on erratic snowfalls. P/E of 93 for April '14 fiscal.
  • IPO Preview: Habit Restaurants
    Thu, Nov. 20 HABT 5 Comments

    Summary

    • High-growth, fast casual restaurant concept that specializes in preparing fresh, made-to-order char-grilled burgers and sandwiches.
    • Market potential 2000 units, currently 99 units. P/E of 73, price-to-sales of 2.3.
    • Rev +49%, Adj net income +50%, total restaurants +36%.
  • IPO Preview: Cnova N.V.
    Thu, Nov. 20 CNV Comment!

    Summary

    • One of the largest global eCommerce companies, with operations in Europe, Latin America, Asia and Africa.
    • Per share dilution about the same as IPO mid-point. Adjusted operating profit a minuscule .04%.
    • -81 P/E, price-to-tangible book of 95, 1.5 price to sales (this is attractive to institutions).
  • IPO Preview: Neothetics
    Thu, Nov. 20 NEOT 1 Comment

    Summary

    • Seeking approval of lead product candidate, LIPO-202, for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients, an indication for which there is no FDA-approved drug.
    • Stockholders & others may purchase up to $27mm, 45%.
    • Price-to-book of 2.9. P/E of -17.5 indicating moderate cash burn relative to market cap.
    • No collaborators. Targeting an aesthetic market. Top line Phase 3 results expected end of '15.
  • IPO Preview: Paramount Group
    Wed, Nov. 19 PGRE 5 Comments

    Summary

    • Vertically-integrated real estate companies REIT focused on owning, operating and managing high-quality, Class A office properties.
    • Expected to yield 2.17% at price range mid-point.
    • Compared to BXP and BPO, 'in the range', see 'valuation' below.
    • Selling 54% on the IPO.
  • IPO Preview: Second Sight Medical Products
    Wed, Nov. 19 EYES 3 Comments

    Summary

    • Medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients.
    • Implanted about 90 units of current product.
    • Laying foundation for major sales growth.
    • Sept. 9 mos rev +88%. Gross margin improved to -14% from -306%. Operating loss is -851% of rev.
  • IPO Preview: STORE Capital Corporation
    Tue, Nov. 18 STOR Comment!

    Summary

    • REIT, that is a leader in the acquisition, investment and management of Single Tenant Operational Real Estate.
    • Discount to Realty Income (O), see 'valuation' below.
    • Expected yield is 5.6% at price range mid-point.
  • IPO Preview: FibroGen
    Fri, Nov. 14 FGEN Comment!

    Summary

    • Research-based, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic agents to treat serious unmet medical needs.
    • Rev +35%, 87% of rev from licenses/milestone payments. Almost breakeven. Price-to-book of 4.
    • AstraZeneca, collaboration partner, to buy $20mm private placement on closing.
    • One product in Phase 3, one in Phase 2.
  • IPO Preview: NeuroDerm
    Fri, Nov. 14 NDRM Comment!

    Summary

    • Clinical-stage pharmaceutical company developing next-generation treatments for central nervous system.
    • No revenue, products based on reformulations.
    • Shareholders may buy $14 million 3.8 times book.
  • IPO Preview: Virgin America
    Fri, Nov. 14 VA Comment!

    Summary

    • Premium-branded, low-cost airline based in California that provides scheduled air travel in the continental United States and Mexico.
    • Price-to-book 2.1, Operating income +51%.
    • Aircraft fuel -1%, lower oil prices expected to be a plus.
  • IPO Preview: eHi Car Services Ltd
    Fri, Nov. 14 EHIC Comment!

    Summary

    • No. 1 car services provider and No. 2 car rentals provider in China in terms of market share by revenues in 2013.
    • 6x sales, still losing money, P/E of -112.
    • Revenue +48%. Price-to-book is 1.8.
  • IPO Preview: Landmark Infrastructure Partners LP
    Fri, Nov. 14 LMRK Comment!

    Summary

    • Growth-oriented master limited partnership formed by Landmark to acquire, own and manage a portfolio of real property interests that it leases to companies in the wireless, billboard & wind industries.
    • 5.75% yield.
    • Price-to-book 1.5. Per share dilution of -28.40.
  • IPO Preview: Navios Maritime Midstream Partners LP
    Thu, Nov. 13 NAP Comment!

    Summary

    • Growth oriented limited partnership formed to own, operate and acquire crude oil tankers under long-term employment contracts.
    • Expected yield of 8.25%.
    • Price-to-book of .8, price-to-tangible book of 1.8.
  • IPO Preview: PRA Health Sciences
    Thu, Nov. 13 PRAH Comment!

    Summary

    • One of the world's leading global contract research organizations by revenue.
    • P/E of -71, Per share dilution -$38, 77% higher than IPO price, Price-to-tangible bk of -1.3.
    • Pre-IPO debt/equity ratio is 1.3, means high interest payments.
  • IPO Preview: Axalta Coating Systems
    Wed, Nov. 12 AXTA Comment!

    Summary

    • Leading global manufacturer, marketer and distributor of high performance coatings systems.
    • Holds the #1 or #2 global market position.
    • Revenue +3%, gross profit +12%, P/E 38, price-to-sales 1.0.
    • All proceeds to shareholders.
  • IPO Preview: EndoStim
    Thu, Oct. 23 STIM Comment!

    Summary

    • A medical device company focused on the development and commercialization of a novel neurostimulation system for the treatment of severe gastroesophageal reflux disease.
    • 2.4 times book. Small rev, large losses.
    • No stockholder interest in the IPO.
  • IPO Preview: Fifth Street Asset Management
    Wed, Oct. 22 FSAM 3 Comments

    Summary

    • A leading alternative asset manager with more than $5.6 billion of assets under management.
    • Proceeds to founding shareholder. Per share dilution same as IPO price.
    • 4.8% yield on Class A stock. Dual stock structure, Class A has 3.8% of votes. P/E of 29, price-to-book of 35.
  • IPO Preview: Proteon Therapeutics
    Wed, Oct. 22 PRTO 2 Comments

    Summary

    • Targeting kidney failure, PRTO initiated the first of two Phase 3 trials for PRT-201 in radiocephalic AVFs, PRTO’s initial indication, in the third quarter of 2014 and expects to initiate the second Phase 3 trial in the first half of 2015.
    • Price-to-book 2.4. P/E -17, no revenue.
    • Stockholders may purchase $30.4mm of the IPO, or 50%.